Flexibility in gene therapy: Adapting to the unique gene therapy demands

Unlocking the future of gene therapy

Gene therapy has developed quickly since its approval in 1990. This rapidly evolving field harnesses viral vectors as vehicles to deliver transformative genetic information, driving breakthroughs in treating rare diseases, cancers and numerous other medical challenges.

The viral-based gene therapy field is currently dominated by four viral vector types: adenovirus, gammaretrovirus, lentivirus and adeno-associated virus. These vectors play a pivotal role in approved treatments. Remarkable advancements such as new serotypes show analytical technology enhancements and vector engineering improvements, but challenges in the field persist:

• Cost barriers 
  Viral-based therapies come with hefty price tags due to expensive reagents, resulting in these therapies often remaining financially out of reach for a large portion of the population.
• Regulatory hurdles 
  As gene therapy is a relatively new modality, trials often lack comprehensive long-term clinical data, making it challenging to assess risks and benefits fully. These uncertainties can lead to approval delays, hindering timely access to potentially life-changing therapies.
• Manufacturing complexities 
  Gene therapies require specialised manufacturing processes, often posing scalability challenges. Ensuring sufficient doses meet therapeutic demands at various project phases is complex.
• Analytical testing demands 
  Regulatory bodies require extensive analytical data to ensure safety and compliance. Developing and validating assays, especially cell-based ones, takes significant time and can impede project progression.

To overcome these challenges, companies have been developing innovative strategies, from in-house GMP plasmid manufacturing to diverse viral vector serotypes and adaptable single-use systems. Moreover, upcoming technologies such as continuous processing and perfusion-based high cell density culture offer glimpses into a more scalable and cost-effective future for gene therapy manufacturing.

In its recent e-book, ReciBioPharm discussed the importance of support at every stage of gene therapy projects. With insights into the evolving gene therapy arena, the publication lays the groundwork for understanding the complexities, breakthroughs and partnerships shaping the future of medicine. Discover how adaptability, innovation and collaborative efforts are propelling gene therapies toward transformative advancements.

To find out more please complete your details below: